Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

Veloce BioPharma

Status and phase

Unknown

Phase 2

Conditions

Warts

Treatments

Drug: VBP-245

Drug: Placebo Gel (no Povidone-Iodine)

Study type

Interventional

Funder types

Industry

Identifiers

NCT04253912

VBP-245-WART2A

Details and patient eligibility

About

This is a multi-center, randomized, double-blind, placebo-controlled phase 2 study in subjects 8 years of age and older who present with verruca vulgaris (common warts) and desire treatment. Subjects may have up to a total of 6 common warts located on their trunk or extremities that will be treated with study medication and followed throughout the study protocol therapy. All warts will be treated two times per day (BID) for12 weeks. Approximately 90 subjects will be enrolled in this study.

Enrollment

90 patients

Sex

All

Ages

8+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject is able to comprehend and is willing to sign an informed consent/assent for participation in this study.
Male or female ≥ 8 years old.
Subject has a clinical diagnosis of verruca vulgaris (common warts).
Subject has up to 6 warts located on the trunk or extremities

Exclusion criteria

Subject has clinically atypical warts on the trunk or extremities.
Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.)
Subject has periungual, subungual, genital, anal, mosaic, plantar, flat, or filiform wart identified as a wart for study treatment.